In patients with SVT, the JAK2/JAK1 inhibitor Ruxolitinib has shown significant activity in reducing the spleen volume,32 but no data are available thus far on whether this finding is associated with fewer recurrences. The gene discussed is JAK1; the disease is Supraventricular tachycardia.